Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 1, 2001, Pages 193-209

  Pepeu, Giancarlo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Animal models; Cholinesterase inhibitors; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GLUCOSE; PHOSPHATASE; PRESENILIN 1;

AGING; ALZHEIMER DISEASE; ANIMAL MODEL; CHOLINERGIC SYSTEM; ENCEPHALITIS; ENERGY METABOLISM; ENZYME INHIBITION; FOREBRAIN; GLUCOSE METABOLISM; MOUSE; NONHUMAN; RAT; REVIEW; TRANSGENIC MOUSE;

EID: 0035112938     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00146-4     Document Type: Article

References (89)

1. Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo
2. A randomized controlled trial of prednisone in Alzheimer's disease
3. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease
4. Paired helical filament-like phosphorylation, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A
5. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease
6. V717F transgenic mouse model of Alzheimer's disease
7. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions
8. The cholinergic hypothesis of geriatric memory dysfunction
9. Cholinergic deafferentation of the rabbit cortex: A new animal model of Aβ deposition
10. Inhibitory effect of a marine sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics
11. Methodological variables in the assessment of β-amyloid neurotoxicity
12. Unilateral and bilateral nucleus basalis lesions: Differences in neurochemical and behavioural recovery
13. Selective loss of cholinergic neurons in Alzheimer's disease
14. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein
15. Memory and cognitive function in man: Does the cholinergic system have a specific role ?
16. Alzheimer disease. Mouse models pave the way for therapeutic opportunities
17. Central cholinergic system and cognition
18. Rodent models for aging processes in human brain
19. Aging, metabolism and Alzheimer disease: Review and hypotheses
20. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor
21. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis
22. Long-term changes in the aggregation state and toxic effects of β-amyloid injected into the rat brain
23. Phosphoprotein phosphatase-activities in Alzheimer's disease brain
24. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats
25. Glial-neuronal interactions in Alzheimer's disease: The potential role of a "Cytokine Cycle" in disease progression
26. Alzheimer's disease: The amyloid cascade hypothesis
27. Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: Relevance to Alzheimer's disease
28. Propionyl-IIGL tetrapeptide antagonizes β-amyloid excitotoxicity in rat nucleus basalis
29. Modulation of β-secretase by HMG-CoA reductase inhibitors
30. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease
31. Peripheral administration of novel anti-inflammatories can attenuate the effect of chronic inflammation within the CNS
32. Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats
33. Animal models in dementia research: Metabolic changes after intracerebroventricular injections of bromopyruvate, AF64A, and Alzheimer brain homogenates
34. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761)
35. Cell and animal models in aging and dementia research
36. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism
37. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer's type ?
38. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: A cross-sectional comparison against advanced late-onset and incipient early-onset cases
39. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice
40. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam
41. β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
42. Microglia: A sensor for pathological events in CNS
43. Effects of Estradiol (-17β) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin
44. The nucleus basalis magnocellularis: The origin of a cholinergic projection to the neocortex of rat
45. Cognitive changes and modified processing of amiloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
46. Lesions of cholinergic forebrain nuclei: Changes in avoidance behavior and scopolamine actions
47. Nonsteroidal anti-inflammatory drugs use and Alzheimer-type pathology in aging
48. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease
49. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
50. The importance of inflammatory mechanisms in Alzheimer's disease
51. Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles
52. High level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
53. Release of Alzheimer amyloid precursors derivatives stimulated by activation of muscarinic receptors
54. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient
55. Delayed behavioral effects following intrahippocampal injection of aggregated Aβ (1-42)
56. Association of diabetes mellitus and dementia: The Rotterdam Study
57. Amnesic properties of scopolamine and brain acetylcholine in the rat
58. Preclinical pharmacology of cholinesterase inhibitors
59. Usefulness, constraints and limits of animal investigations in the study of aging brain and senile dementia
60. The brain cholinergic system in ageing mammals
61. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain ?
62. The role of microglia in the cortical neuropathology of Alzheimer's disease
63. No hippocampal neuron or synaptic bouton loss in learning-impaired aged β-amyloid precursor protein
64. Behavioral screening for cognition enhancers from indiscriminate to valid testing Part I and Part II
65. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats
66. β(1-40) Amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical γ-aminobutyric acid release in vivo
67. Brain inflammatory reaction in an animal model of regional degeneration and its modulation by an antiinflammatory drug: Implication in Alzheimer's disease
68. A double-blind, placebo controlled trial of diclofenac/misoprostol in Alzheimer's disease
69. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
70. Transgenic animals relevant to Alzheimer's disease
71. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease
72. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain
73. β-Sheet breakers peptides as a novel strategy to inhibit and dissolve amyloid deposits
74. Glial cytokines as neuropathogenic factors in HIV infection: Pathogenic similarities to Alzheimer's disease
75. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
76. Ganglioside loss is a primary event in Alzheimer disease type I
77. Prevalence of chronic diseases in older Italians: Comparing self-reported and clinical diagnoses
78. Single and multiple transgenic mice as models for Alzheimer's disease
79. The cause of neuronal degeneration in Alzheimer's disease
80. Behavioral, biochemical, histological and electrophysiological effects of 192 Ig-saporin injection into basal forebrain of rat
81. The pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain of rats
82. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-I and amyloid precursors protein transgenes
83. Protective effects of idebenone and α-tochopherol on β-amyloid (1-42)-induced learning and memory deficits in rats: Implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo
84. Neurotrophic and neurotoxic effects of amyloid-β-protein: Reversal by tachykinin neuropeptides